Women may be more susceptible to adverse eventsBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7071.1552c (Published 14 December 1996) Cite this as: BMJ 1996;313:1552
- Maggie Phillips
- Medical director Travellers' Medical and Vaccination Centre, Adelaide, Australia
EDITOR,—The methodology that P J Barrett and colleagues used in their study comparing adverse events associated with mefloquine with those associated with chloroquine plus proguanil for antimalarial prophylaxis1 is similar to that used in a study that Kass and I carried out.2 We, however, compared mefloquine with doxycycline, which is widely used by Australians and North Americans as the alternative to mefloquine for travellers to chloroquine …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial